Figure 2 CCND2 mRNA level in the indicated groups and its correlations with clinical characteristics of HCC. (A) CCND2 mRNA levels differed significantly among the 4 groups (HCC vs. LC, P<0.001; HCC vs. CHB, P<0.001; HCC vs. HCs, P<0.001). (B) mRNA levels in HCC patients differed significantly between advanced tumor node metastasis (TNM) stage (III/IV) and early TNM stage (I/II; P=0.030). (C) mRNA level was not correlated with age in 118 HCC patients (P=0.297). (D–G) mRNA levels in HCC patients did not significantly differ between HBeAg-positive and HBeAg-negative patients (P=0.595), male and female patients (P=0.059), smokers and non-smokers (P=0.085), or drinkers and non-drinkers (P=0.533). (H) mRNA levels and serum AFP levels were not significantly correlated in HCC patients (P=0.669). (I–K) mRNA levels did not significantly differ between HCC patients with a single tumor and those with multiple tumors (P=0.959), those with tumors ≤5 cm and those with tumors >5 cm (P=0.100), or HCC patients with and without vascular invasion (P=0.055). (L) mRNA levels did not differ among CTP stages within the HCC group (A vs. B, P=0.796; A vs. C, P=0.811; B vs. C, P=0.602).